News Briefs: Monoclonal Antibodies Yield Mixed Results Against Omicron | Dec. 22, 2021

Regeneron Pharmaceuticals’ monoclonal antibody treatment for COVID-19 has “diminished potency” when used against the omicron variant, while AstraZeneca plc’s antibody product “retained neutralizing activity” against the new variant. The antibody treatments remain the standard of care for unvaccinated COVID-19 patients with severe disease. Regeneron emphasized that its treatment is effective against the delta variant. However, omicron has become the dominant variant in recent days: the Associated Press reported 73% of new infections last week were omicron.

© 2022 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

stethoscope-and-clipboard
December 8

ICER Report Finds Over $800 Million in Clinically Unsupported Drug Price Hikes During 2021

READ MORE
businessman-viewing-news-update-journalism-headline-on-a-laptop
December 8

News Briefs: Manufacturers Reset Lobbying Strategy After Medicare Negotiation Loss

READ MORE
pills
December 8

Mark Cuban Pharmacy, Employer-Owned PBM Offer New ‘Supplemental Drug Discount Product’

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today